The Food and Drug Administration is aiming to give full authorization to the Pfizer-BioNTech coronavirus vaccine by Monday, sources familiar with the matter told the New York Times on Friday.
All coronavirus vaccines currently offered in the U.S. — produced by Pfizer and BioNTech, Moderna, and Johnson & Johnson — currently have emergency authorization from the FDA. As of Friday, 62 percent of Americans, or about 205 million residents, have received one of the three vaccines with emergency authorization.
The granting of full approval of the Pfizer-BioNTech vaccine may give impetus to various public and private entities looking for greater approval from regulators to institute vaccination mandates.
The FDA declined to comment to the Times on the granting of full approval.
Send a tip to the news team at NR.